Sublocade vs Vivitrol
Both are monthly injections. Both treat opioid use disorder. Both cost about the same. That is where the similarities end. Sublocade is buprenorphine, an opioid agonist. Vivitrol is naltrexone, an opioid blocker. They are pharmacological opposites and they fit very different patients.
| Attribute | Sublocade (extended-release buprenorphine) | Vivitrol (extended-release naltrexone) |
|---|---|---|
| Drug class | Partial opioid agonist | Full opioid antagonist |
| FDA approval | Opioid use disorder | Opioid use disorder + alcohol use disorder |
| Schedule | Schedule III controlled substance | Not controlled |
| Injection site | Subcutaneous (abdomen) | Intramuscular (gluteal) |
| Frequency | Once monthly | Once monthly |
| Pre-treatment requirement | 7 days on transmucosal buprenorphine first | 7 to 10 days fully opioid-free |
| Withdrawal during induction | Mild, managed by sublingual buprenorphine | Risk of precipitated withdrawal if not fully opioid-free |
| Cravings reduction | Strong - constant agonist effect | Moderate - works through receptor blockade |
| Cost without insurance | ~$1,580 per shot | ~$1,500 per shot |
| Storage | Refrigerated; provider only | Refrigerated; provider only |
| REMS program required | Yes - Sublocade REMS | No |
| Reversibility on overdose | Naloxone may have limited effect at high doses | Naloxone fully effective |
| Discontinuation | Buprenorphine levels detectable for months | Receptors come back online over 7 to 14 days |
The mechanism gap
Sublocade releases buprenorphine slowly out of a depot under the skin. It keeps a steady opioid agonist effect on receptors for 28 days, eliminating withdrawal and reducing cravings. Vivitrol releases naltrexone over the same window but does the exact opposite: it locks opioid receptors so nothing can activate them, including the patient's own opioids if they relapse.
Patients sometimes assume the two are interchangeable because both are called "monthly injections for opioid use disorder." They are not. If you give a patient who is using fentanyl a Sublocade shot, they will be okay. If you give that same patient a Vivitrol shot, they will be in severe precipitated withdrawal within minutes.
Who Sublocade fits
- Patients who do well on Suboxone but cannot maintain daily adherence
- Patients who travel for work or have unstable housing
- Patients in early recovery (under 6 months) where withdrawal management still matters
- Patients with high-dose opioid history who need ongoing receptor occupancy
Who Vivitrol fits
- Patients who have completed detox and are stable
- Patients who do not want to be on an opioid medication of any kind
- Patients with co-occurring alcohol use disorder
- Patients with employment or legal situations where opioid medications are a problem
The induction question
Sublocade requires a week of stable transmucosal buprenorphine first. That is a feature, not a bug. The week of sublingual buprenorphine ensures the patient tolerates the medication and is engaged in treatment before committing to a monthly depot.
Vivitrol requires the opposite preparation: a week to ten days fully opioid-free. For a patient leaving residential treatment, that is built into the program. For a patient walking in off the street, it is the single biggest barrier to starting.
Cost comparison
Both medications run roughly $1,500 to $1,600 per shot at AWP. Both are covered by every state Medicaid program. Both have manufacturer copay assistance programs for commercial insurance patients. The financial difference is negligible at the patient level. Provider revenue per shot is similar. The decision should turn on clinical fit, not cost.
The honest take
For a patient in active opioid use disorder, Sublocade is easier to start and produces better short-term retention. For a patient who has detoxed and wants to stay off opioids entirely, Vivitrol is the better tool. Picking between them at the wrong stage of treatment is the most common avoidable mistake.